Browse News
Filter News
Found 37 articles
-
Dyno Therapeutics Launches Dyno eCap 1™ Vector, a Field-Leading AAV Capsid for Eye Gene Therapies
10/25/2023
Dyno Therapeutics Launches Dyno eCap 1™ Vector, a Field-Leading AAV Capsid for Eye Gene Therapies.
-
Dyno Therapeutics to Present on Breakthrough Optimized AAV Capsids for Eye and CNS Gene Delivery at ESGCT Annual Congress
10/11/2023
Dyno Therapeutics, Inc. today announced a Dyno Scientific Symposium and the presentation of three research abstracts at the upcoming 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT) being held October 24-27, 2023 in Brussels, Belgium.
-
Dyno Therapeutics Launches the Dyno bCap 1™ Capsid Product, a Breakthrough CNS Gene Delivery Vector Created with Generative Artificial Intelligence
5/19/2023
Dyno Therapeutics, Inc. today announced the launch of its Dyno bCap 1™ capsid product, a breakthrough CNS-targeted AAV gene delivery vector with best-in-class potential, in a keynote address at the company’s Scientific Symposium at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting.
-
Dyno Therapeutics to Present New Data on Optimized AAV Capsids with Transformative Therapeutic Delivery Potential at 2023 Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
5/2/2023
Dyno Therapeutics, Inc. today announced a Dyno Scientific Symposium and the presentation of four research abstracts at the upcoming 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) being held May 16-20, 2023 in Los Angeles, Calif.
-
Astellas named a new president and CEO and announced additional changes to its leadership structure in an effort to accelerate growth and chart its long-term business trajectory.
-
Excision BioTherapeutics to Host Key Opinion Leader Webinar on HIV and the Ongoing Phase 1/2 Trial Evaluating EBT-101 as a Potential Cure
10/20/2022
Excision BioTherapeutics, Inc., a clinical-stage biotechnology company developing CRISPR-based therapies intended to cure viral infectious diseases, today announced it will host a clinical expert webinar on HIV and the ongoing Phase 1/2 trial evaluating the Company’s CRISPR-based therapy EBT-101 as a potential cure for the disease.
-
Weston Miller, M.D., senior medical director of clinical development at Astellas Gene Therapies, called the positive interim and tolerability data an important waypoint.
-
GRO Biosciences Appoints Rakhshita Dhar to its Board of Directors
1/18/2022
GRO Biosciences Inc. today announced the appointment of Rakhshita Dhar to its Board of Directors.
-
BioSpace is proud to present its NextGen Bio “Class of 2022,” a list of up-and-coming life sciences companies in North America that recently launched.
-
BioSpace Announces Top New Biopharma Companies to Watch in 2022
1/5/2022
BioSpace, Inc., the leading life sciences news and careers site, has announced their selections for the industry’s most exciting up-and-coming companies in 2022.
-
From the continuing fight against COVID-19 to new companies emerging in exciting therapeutic areas to the people who mattered most, here’s a look at just some of the biggest successes, most dramatic flops – and a few that fall somewhere in between.
-
With this new collaboration, Astellas will take advantage of Dynos' next-gen AAV vectors to deliver its gene therapy.
-
Astellas and Dyno Therapeutics Announce Research Collaboration to Develop Next-Generation AAV Gene Therapy Vectors for Skeletal and Cardiac Muscle
12/1/2021
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Dyno Therapeutics, Inc. (President and CEO: Eric Kelsic, Ph.D., "Dyno") today announced an option and license agreement was signed on November 23 to develop next-generation adeno-associated virus (AAV) vectors for gene therapy directed to skeletal and cardiac muscle using Dyno's CapsidMap™ platform.
-
With the Thanksgiving holiday upon us, BioSpace felt it was important to give thanks for some of the positive things that have happened this year. And there are many!
-
The United States has seen companies launching left and right. Check out the top 10 biopharma Series A rounds in the U.S. so far this year.
-
Roche will apply RNAfix and Shape’s AAVid technology platform to develop next-generation tissue-specific adeno-associated viruses for new gene therapies aimed at these indications.
-
Money on the Move: May 5 - 11
5/12/2021
Catch up on the investment news quickly with BioSpace's brief overview of the biotech companies hitting the Nasdaq and raking in fresh cash the past week. -
Dyno Therapeutics Presents State-of-the-Art Applications of Machine Learning to Design Improved AAV Capsids for a Broad Range of Gene Therapies at American Society of Gene and Cell Therapy Conference
5/11/2021
Dyno Therapeutics , a biotechnology company applying artificial intelligence (AI) to gene therapy, will describe ongoing enhancements to its machine learning platform in three oral presentations at the 24th annual meeting of the American Society of Gene and Cell Therapapies
-
Since emerging from stealth mode in 2020 Dyno Therapeutics has been busy advancing its gene therapy platform. This morning, the company bolsters its research with $100 million raised in a Series A financing round.
-
Dyno Therapeutics Closes $100 Million Series A Financing Led by Andreessen Horowitz to Accelerate AI‑powered Gene Therapy Platform
5/6/2021
Dyno Therapeutics, Inc. , a biotechnology company applying artificial intelligence (AI) to gene therapy, today announced a $100 million Series A financing led by Andreessen Horowitz, with participation from a select syndicate of new investors